Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Most participants approach weight loss plateau around weeks 40-48, though clinical trial data showed participants were still losing weight at study conclusion, suggesting even longer treatment courses might yield additional benefits
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
M.HassaballahA
Handling and use of these products should be restricted to suitably qualified professionals
US$ 25.28
US$ 29.76
US$ 29.22
US$ 24.16
